Unexplained female infertility. Female infertility of other origin
Conditions
Interventions
Intervention 1: Intervention group: Patients of this group will receive simvastatin 20 mg daily orally for 45 days before the start of the ovarian stimulation cycle. After the end of the intervention,
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: Women between 20-40 years old with unexplained infertility Serum Tumor Necrosis Factor (TNFa) > 5 pg/ml
Exclusion criteria
Exclusion criteria: History of liver, kidney and muscular diseases History of metabolic diseases such as diabetes or thyroid dysfunction History of organic or function genital disorder History of medication with neurological , cardiovascular and metabolic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of Tumor Necrosis Factor (TNFa). Timepoint: Screening, End of intervention (day 45). Method of measurement: Elisa technique. | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin 1 serum level. Timepoint: Screening, End of intervention (day 45). Method of measurement: Elisa technique.;Humanuman chorionic gonadotropin Beta (ßhCG). Timepoint: Two weeks after embryo transfer. Method of measurement: Elisa technique.;C reactive protein serum level. Timepoint: Screening, End of intervention (day 45). Method of measurement: Immunoturbidimetry.;Clinical Pregnancy. Timepoint: 5 weeks after embryo transfer. Method of measurement: Detection of fetal heart rate (FHR) in trans-vaginal ultrasound.;Adverse Events. Timepoint: During the study period from randomization to the end of the first month after embryo transfer. Method of measurement: Interview and physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzra Motaghinejad
Iran University of Medical Sciences
Outcome results
None listed